Fulltext

Characterization of β-d-N4-Hydroxycytidine as a Novel Inhibitor of Chikungunya Virus

Ehteshami M 1 , Tao S 1 , Zandi K 1 , Hsiao HM 1 , Jiang Y 1 , Hammond E 1 Show all authors , Amblard F 1 , Russell OO 1 , Merits A 2 , Schinazi RF 3

Affiliations 

  • 1 Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA
  • 2 Institute of Technology, University of Tartu, Tartu, Estonia
  • 3 Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA rschina@emory.edu
Antimicrob Agents Chemother, 2017 04;61(4).
PMID: 28137799 DOI: 10.1128/AAC.02395-16

Abstract

Chikungunya virus (CHIKV) represents a reemerging global threat to human health. Recent outbreaks across Asia, Europe, Africa, and the Caribbean have prompted renewed scientific interest in this mosquito-borne alphavirus. There are currently no vaccines against CHIKV, and treatment has been limited to nonspecific antiviral agents, with suboptimal outcomes. Herein, we have identified β-d-N4-hydroxycytidine (NHC) as a novel inhibitor of CHIKV. NHC behaves as a pyrimidine ribonucleoside and selectively inhibits CHIKV replication in cell culture.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications